Corporate ActionJun 3, 2026, 06:01 AM
Mineralys Repurchases Royalty for $200M; Secures $500M Loan, $150M Offering
AI Summary
Mineralys Therapeutics announced a series of strategic financial transactions. The company repurchased all future royalty payments for lorundrostat from Tanabe Pharma Corporation for $200 million upfront and up to $100 million in commercial milestones, aiming to capture incremental value from future sales. Concurrently, Mineralys secured a $500 million senior secured term loan facility from Pharmakon Advisors, with $100 million funded at closing, significantly strengthening its balance sheet. Additionally, the company priced an underwritten offering of approximately $150 million of its common stock.
Key Highlights
- Repurchased lorundrostat royalty obligation from Tanabe for $200M upfront.
- Up to $100M additional payment to Tanabe upon commercial milestones.
- Secured $500M senior secured term loan facility from Pharmakon Advisors.
- First tranche of the loan facility provides $100M at closing.
- Priced an underwritten offering of approximately $150M of common stock.
- Loan matures in June 2031, bearing interest at SOFR (3.25% floor) + 5.50%.
- Aggregate potential future milestone payments to Tanabe up to $265M.
Price Impact
More from MLYS